Abstract
We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.
| Original language | English |
|---|---|
| Pages (from-to) | 13-16 |
| Number of pages | 4 |
| Journal | Japanese Journal of Antibiotics |
| Volume | 50 |
| Issue number | 11 |
| Publication status | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine
Cite this
Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections. / Shinagawa, Nagao; Takeda, Shozo; Oohira, Sei Ichi; Yasuda, Yoshikazu; Fujisaki, Masato; Saito, Hidetsugu; Ueda, Masakazu; Mitamura, Keiji; Nishio, Takeki; Itakura, Masaru; Koyama, Masaru; Hirano, Masanori; Ohyama, Rempei; Kako, Makoto; Amako, Yoshihisa; Okuda, Koichi; Iwasa, Takehiko; Sugiyama, Atsushi; Hirano, Makoto; Takashima, Shigeki; Ohsawa, Nakaaki; Nakaya, Seishi; Yamada, Minoru; Zeze, Fujio; Tanaka, Shinnosuke; Yatsuka, Kohta; Ishii, Jun.
In: Japanese Journal of Antibiotics, Vol. 50, No. 11, 1997, p. 13-16.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections
AU - Shinagawa, Nagao
AU - Takeda, Shozo
AU - Oohira, Sei Ichi
AU - Yasuda, Yoshikazu
AU - Fujisaki, Masato
AU - Saito, Hidetsugu
AU - Ueda, Masakazu
AU - Mitamura, Keiji
AU - Nishio, Takeki
AU - Itakura, Masaru
AU - Koyama, Masaru
AU - Hirano, Masanori
AU - Ohyama, Rempei
AU - Kako, Makoto
AU - Amako, Yoshihisa
AU - Okuda, Koichi
AU - Iwasa, Takehiko
AU - Sugiyama, Atsushi
AU - Hirano, Makoto
AU - Takashima, Shigeki
AU - Ohsawa, Nakaaki
AU - Nakaya, Seishi
AU - Yamada, Minoru
AU - Zeze, Fujio
AU - Tanaka, Shinnosuke
AU - Yatsuka, Kohta
AU - Ishii, Jun
PY - 1997
Y1 - 1997
N2 - We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.
AB - We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.
UR - http://www.scopus.com/inward/record.url?scp=33749302858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749302858&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33749302858
VL - 50
SP - 13
EP - 16
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
SN - 0368-2781
IS - 11
ER -